CoAprovel

Quick links to important sections

CoAprovel

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of CoAprovel

What is CoAprovel?

CoAprovel is a fixed-dose combination medication used in the management of high blood pressure, also known as hypertension. It contains two active substances that work in different ways to help lower blood pressure: irbesartan and hydrochlorothiazide.

Components and Mechanism of Action

  • Irbesartan: This component belongs to a group of medicines known as angiotensin-II receptor antagonists. Angiotensin-II is a substance produced in the body that binds to receptors in blood vessels, causing them to tighten and narrow. This narrowing leads to an increase in blood pressure. Irbesartan works by blocking these receptors, allowing the blood vessels to relax and widen, which helps to lower blood pressure.
  • Hydrochlorothiazide: This component is a thiazide diuretic, often referred to as a "water pill." It works by increasing the amount of salt and water excreted from the body through urine. By reducing the volume of fluid circulating in the blood vessels, it further assists in reducing blood pressure.

Therapeutic Use

CoAprovel is typically used when treatment with a single active substance has not sufficiently controlled blood pressure. By combining two mechanisms of action into one tablet, the medication provides a cumulative effect to help achieve target blood pressure levels. Maintaining blood pressure within a normal range is essential for reducing the long-term risk of cardiovascular complications.

What side effects are possible with CoAprovel ?

The safety profile of CoAprovel (irbesartan/hydrochlorothiazide) is a composite of the officially documented adverse reactions from both the Angiotensin II Receptor Antagonist (Irbesartan) and the Thiazide Diuretic (Hydrochlorothiazide) components, organized by frequency and physiological system in regulatory documents.

Official Adverse Reaction Classifications

The most frequent documented adverse effect, classified as Very Common, is hypokalaemia (low potassium levels), which is associated with the diuretic component. Side effects classified as Common include dizziness (particularly orthostatic dizziness), fatigue, nausea, vomiting, and headache. Uncommon reactions cover events such as syncope, tachycardia, oedema, and certain skin reactions like rash and pruritus.

Adverse effects are also formally grouped by System-Organ-Class, detailing documented reactions within the Blood and lymphatic system disorders, Metabolism and nutrition disorders, Nervous system disorders, Vascular disorders, and Gastrointestinal disorders categories, among others.

Serious Safety Considerations and Constraints

Official regulatory labeling highlights the potential for serious adverse reactions, including Angioedema (swelling of the face, lips, or throat) and, rarely, Hepatic failure or Respiratory distress (pneumonitis and pulmonary oedema).

Symptomatic hypotension may occur, specifically noted as being more likely after the initial dose in volume-depleted patients. Furthermore, the medicine is subject to explicit safety constraints. It is contraindicated in individuals with known hypersensitivity to sulfonamide-derived substances, those with severe renal impairment, severe hepatic impairment, or women who are in the second and third trimesters of pregnancy.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with CoAprovel is primarily characterized by the combined effects of its two components, irbesartan and hydrochlorothiazide. Since overdose can have serious consequences, it is essential to seek immediate medical attention or contact a poison control center right away if an overdose is suspected, regardless of immediate symptoms.

Documented Overdose Manifestations

The most likely effects of an irbesartan overdose are expected to be changes in the cardiovascular system, specifically hypotension (low blood pressure) and a disturbance in heart rate, such as tachycardia (rapid heartbeat) or potentially bradycardia (slow heart rate).

Overdose with the diuretic component, hydrochlorothiazide, is commonly associated with an imbalance of body fluids and electrolytes. This can manifest as dehydration resulting from excessive urine production (diuresis) and electrolyte depletion (low levels of potassium, chloride, and sodium). Common general symptoms may include nausea and somnolence (drowsiness).

Treatment and Management

Official regulatory guidance specifies that treatment for a CoAprovel overdose should be symptomatic and supportive. There is no specific antidote. It is important to note that irbesartan is not removed by haemodialysis, and the degree to which hydrochlorothiazide may be removed by haemodialysis is not definitively established.

Therapeutic Uses of CoAprovel

What CoAprovel Treats: Main Uses and Benefits

CoAprovel (irbesartan/hydrochlorothiazide) is a combination medication that is applied in addressing conditions associated with high blood pressure. The combination is considered relevant across domains where additional symptomatic support is needed. This fixed-dose combination is generally relevant for individuals experiencing conditions where symptoms may intensify temporarily.

The two-component approach supports patients by contributing to easing the overall symptom load, and is commonly used across conditions presenting with acute episodes. Irbesartan may assist with symptoms related to heightened physiological activity, while hydrochlorothiazide is commonly used to help with symptoms related to systemic imbalance. This combination assists with maintaining functional stability and is relevant in clinical settings that involve acute or unstable symptom patterns.

Quick Fact: Helps ease symptoms related to heightened physiological activity

Eligibility and Restrictions for Use

Who can and cannot use CoAprovel?

This information defines eligibility based strictly on government regulatory documents, outlining who is allowed, who is restricted, and who is contraindicated for the use of CoAprovel (Irbesartan/Hydrochlorothiazide).

Category Official Regulatory Status
Allowed Population Adults with essential hypertension not adequately controlled by single-agent therapy.
Age Limitations Not recommended for children and adolescents (< 18 years) as safety and efficacy have not been established. Older adults do not typically require a dosage adjustment.
Pregnancy/Lactation Contraindicated in the second and third trimesters of pregnancy. Not recommended during the first trimester or while breastfeeding.
Absolute Contraindications Hypersensitivity to the drug or sulfonamide-derived substances. Severe renal impairment (creatinine clearance < 30 mL/min) or anuria. Severe hepatic impairment, biliary cirrhosis, or cholestasis. Refractory hypokalaemia or hypercalcaemia. Concomitant use with aliskiren in diabetic or renally impaired patients.
Conditional Use Patients with volume or sodium depletion must have this condition corrected before beginning therapy. Use with caution is advised for patients with mild to moderate impaired hepatic function.

The regulatory profile strictly establishes that the medicine is reserved for adults who require dual therapy, and prohibits use based on non-negotiable health criteria, including severe organ dysfunctions (kidney and liver) and later stages of pregnancy.

What should I know about interactions with other medicines?

Official Interaction Constraints for CoAprovel

CoAprovel (irbesartan/hydrochlorothiazide) has documented interaction patterns based on its two active components, which are strictly outlined in government regulatory information.

Contraindicated Combinations

Co-administration is formally restricted when combining CoAprovel with agents that induce dual blockade of the Renin-Angiotensin-Aldosterone System (RAAS). Specifically, co-use with Aliskiren-containing products is contraindicated in patients with Diabetes Mellitus or renal impairment. Furthermore, official regulatory documents restrict the combination with ACE-inhibitors in patients presenting with diabetic nephropathy.

Clinically Significant Interactions

  • Potassium-Modifying Agents: Co-administration with potassium-sparing diuretics or potassium supplements may increase the risk of hyperkalemia due to the Irbesartan component. Conversely, agents like corticosteroids can potentiate the risk of hypokalemia from Hydrochlorothiazide.
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Combining with NSAIDs increases the documented risk of renal impairment and can officially reduce the antihypertensive effect.
  • Metabolic and Absorption Alterations: Irbesartan exposure may be increased by CYP2C9 inhibitors. The absorption of Hydrochlorothiazide is reduced when co-administered with Cholestyramine or Colestipol resins.
  • Alcohol: Consumption of alcohol is noted as potentially potentiating orthostatic hypotension.

Mechanism of Action

The combined physiological activity of CoAprovel relies on the simultaneous modulation of two independent systems that regulate systemic pressure: vascular resistance and circulating fluid volume.

The Irbesartan component acts as a selective competitive antagonist of the Angiotensin II Type 1 ( AT1) receptor. This receptor mediates vasoconstriction within the Renin-Angiotensin-Aldosterone System (RAAS). By blocking AT1, Irbesartan prevents Angiotensin II binding, initiating a cascade that leads to the relaxation of vascular smooth muscle and a reduction in systemic vascular resistance.

Simultaneously, Hydrochlorothiazide operates by inhibiting the Sodium-Chloride ( Na^+- Cl^-) Symporter (NCC) in the kidney's distal convoluted tubule.

This action reduces the reabsorption of Na^+ and Cl^- ions. The resulting osmotic gradient leads to increased excretion of water and a subsequent reduction in circulating plasma volume.

These mechanisms are additive and complementary. The AT1 blockade mitigates the RAAS counter-regulatory reflex—which would typically promote fluid retention in response to volume loss—allowing for sustained modulation of both vascular resistance and fluid volume.

Dosage and Administration Information

Administration Guidelines for CoAprovel

CoAprovel is a fixed-dose combination medication used in the management of essential hypertension. The following text details the standardized procedures for administration, dosing, and schedule.


Dosing and Administration Protocol

The approved route of administration for this medicine is oral use via a film-coated tablet. The medication is to be taken once daily to maintain a consistent administration pattern. The tablet may be administered with or without food and should be swallowed with sufficient fluid.

Instruction Category Regimen Details
Starting Dose Typically 150 mg Irbesartan / 12.5 mg Hydrochlorothiazide once daily.
Maximum Dose 300 mg Irbesartan / 25 mg Hydrochlorothiazide once daily.
Dose Adjustment Dose progression (titration) can occur sequentially, generally after 1 to 2 weeks of therapy, if necessary.

Procedural Constraints and Special Populations

Treatment must adhere to specific procedural constraints. If a daily dose is forgotten, the instruction is to take the next scheduled dose; a double dose must not be taken to compensate for the missed one. Additionally, volume or sodium depletion should be corrected prior to initiation of administration. The medicine is not recommended for use in the pediatric population (under 18 years of age).

Administration is also constrained by renal function: the combination is not recommended for patients who have severe renal dysfunction, defined as a creatinine clearance of less than 30 mL/min.

Recent Clinical Evidence

CoAprovel: Overview of Clinical Studies

Clinical evidence concerning the fixed-dose combination of Irbesartan and Hydrochlorothiazide (HCTZ) primarily involves studies of its blood pressure (BP)-lowering effects in adults with essential hypertension. The combination is typically studied in patients whose blood pressure is not adequately controlled by either Irbesartan or HCTZ alone.

Effects on Blood Pressure

  • Combination vs. Monotherapy: Studies have shown that the fixed-dose combination of Irbesartan and HCTZ generally results in a greater reduction in diastolic and systolic BP compared to the individual components (Irbesartan or HCTZ) used as monotherapy.
  • Severe Hypertension: In trials involving patients with more severe, uncontrolled hypertension, treatment with the combination was associated with a more rapid and substantial reduction in BP compared to Irbesartan monotherapy. A higher percentage of patients in these studies achieved target BP goals with the combination.
  • Dose Response: Increasing the dose of the components, particularly Irbesartan, has been observed in some studies to produce a further incremental decrease in blood pressure, supporting a dose-related response.

Tolerability and Safety Findings

Clinical trials have assessed the short-term tolerability of the combination. The most commonly reported side effects across studies include dizziness, fatigue, nausea, and vomiting. Laboratory abnormalities, such as changes in blood urea nitrogen and creatinine levels, were also noted.

Observation Key Finding in Studies
Electrolytes Irbesartan component may attenuate (lessen) the risk of hypokalemia (low potassium) that is sometimes associated with HCTZ (diuretic) use alone.
Metabolic Markers At the HCTZ dose (12.5 mg) contained in the combination, minimal effects on cholesterol and triglyceride levels were reported, though thiazides in general can be associated with such increases.
Discontinuation In placebo-controlled trials, discontinuation due to adverse events was generally comparable between the combination group and the placebo group.

Key Studies & References

  1. Effectiveness of Angiotensin Receptor Blockers (ARB) and Hydrochlorothiazide Compared to ARB Monotherapy in the Control of Hypertension among Adult Patients: A Systematic Review and Meta-Analysis

Frequently Asked Questions (FAQ)

Common questions about CoAprovel (FAQ)

Q: How quickly does CoAprovel start to lower blood pressure?

A: The diuretic component of CoAprovel is described as having an onset of effect within a few hours. However, official information indicates that the full, stable blood pressure lowering effect from the combination is usually achieved after 6 to 8 weeks of starting treatment.


Q: Can CoAprovel be stopped suddenly if I feel better?

A: The regulatory guidance for CoAprovel advises that you should not stop taking this medication suddenly or change the dosage on your own. This is the documented procedure for this medicine, and any change to the regimen should be discussed with a healthcare provider.


Q: Are there any foods or drinks I need to avoid while taking CoAprovel?

A: Official prescribing information notes potential interactions with alcohol, as regulatory information notes that it can increase the risk of dizziness. Specific dietary caution is advised regarding potassium-containing salt substitutes and mathbfliquorice due to the risk of electrolyte imbalance.


Q: Is CoAprovel taken in the morning or at night?

A: CoAprovel is prescribed to be taken once daily. Official guidance often recommends taking it in the morning. This is to help prevent the diuretic component from potentially interrupting sleep due to increased urination.


Q: How long do I usually need to take CoAprovel?

A: The medicine is intended to control high blood pressure, not cure the underlying condition. For chronic conditions like essential hypertension, treatment is typically indicated for long-term control of blood pressure.


Q: Is CoAprovel safe for people with diabetes?

A: Official warnings advise caution for use in individuals with diabetes, as the diuretic component may impair glucose tolerance. Official constraints also strictly contraindicate the combination with Aliskiren in diabetic patients, and the Irbesartan component has been associated with reports of low blood sugar (hypoglycaemia).


Q: Does CoAprovel interact with supplements like potassium or magnesium?

A: Official documents explicitly mention interactions with potassium supplements and salt substitutes. Additionally, because the diuretic component can lead to magnesium loss, caution is noted regarding drugs containing magnesium that have a laxative effect.


Q: Does CoAprovel cause frequent urination?

A: The hydrochlorothiazide component of CoAprovel is a thiazide diuretic (or water pill). The primary function of a diuretic is to cause the kidneys to increase urine output, which is a normal pharmacological effect intended to reduce blood volume.


Q: Does taking CoAprovel affect my ability to drive?

A: The official product information advises caution because the medicine may cause adverse effects like dizziness or weariness (fatigue). Official guidance indicates that if dizziness or weariness is experienced, driving or operating machinery should be avoided.


Q: Are there long-term side effects of taking CoAprovel for many years?

A: Long-term, cumulative use of the hydrochlorothiazide component (the diuretic) is specifically associated with an increased risk of non-melanoma skin cancer. Official warnings regarding this risk highlight the importance of regularly checking the skin for any suspicious lesions.


Q: Can CoAprovel be split or crushed to make it easier to swallow?

A: Official administration guidelines state that the tablet should be swallowed whole. It is explicitly noted that the tablet should not be broken, crushed, or chewed before being swallowed.


Q: Does CoAprovel interact with cold or flu medicines?

A: Caution is generally advised because some common cold and flu treatments may interact. Specifically, both certain pain relievers (like NSAIDs) and medicines containing decongestants can potentially reduce the effectiveness of the blood pressure lowering effect.


Q: Will CoAprovel cure my high blood pressure?

A: According to official patient information, this medicine is used to control high blood pressure, but it does not cure the condition. Consistent use is generally required to maintain blood pressure within the target range.


Q: Does CoAprovel cause muscle cramps?

A: While not listed as a common side effect, muscle pain or cramps are documented as possible warning signs of a fluid or mathbfelectrolyte mathbfimbalance. Such imbalances are described as a potential consequence of the diuretic component.


Q: Does CoAprovel affect blood sugar levels?

A: Regulatory documents indicate the medicine can affect blood sugar levels. The diuretic component may impair the body’s ability to use glucose effectively (mathbfglucose mathbftolerance), and the Irbesartan component has been associated with reports of low blood sugar (hypoglycaemia).


Q: What if my blood pressure remains high even while taking CoAprovel?

A: If the blood pressure is not adequately lowered after a period of use, official guidance indicates that the healthcare provider may modify the current therapy. This modification may involve changing the current medicine or adding another mathbfantihypertensive mathbfdrug to the treatment regimen.


Q: Do researchers know if CoAprovel is effective across all ethnic groups?

A: Clinical data reviewed by regulatory authorities indicates that the medicine is effective in a wide range of patients. This includes data demonstrating its effectiveness among various racial and ethnic minorities.


Q: Is it necessary to have blood tests while taking CoAprovel?

A: Periodic monitoring of blood serum levels is generally recommended during treatment. Monitoring may commonly involve checking serum levels of mathbfelectrolytes (such as potassium) and markers of mathbfkidney mathbffunction (such as creatinine).


Q: Can men taking CoAprovel experience sexual side effects?

A: Official documents, including post-marketing reports, have documented the occurrence of sexual side effects. These have included reports of mathbflibido mathbfdisorder and mathbfsexual mathbfdysfunction.


Q: Does CoAprovel make you sensitive to the sun?

A: The medicine may cause photosensitivity, which is an increased skin sensitivity to sunlight. Due to this possibility, official guidance suggests limiting exposure to direct sunlight and mathbfUV mathbfrays.


Q: Does CoAprovel cause a persistent cough like some other blood pressure medicines?

A: Cough has been reported as an adverse reaction in clinical trials. However, the official data indicates that the reported rate is typically low and comparable to the rate observed in patients taking a placebo.


Q: Is it true that CoAprovel can cause an increase in uric acid?

A: According to official warnings, the medicine may cause an increase in uric acid levels (mathbfhyperuricaemia). This effect, associated with the diuretic component, may lead to the precipitation of gout in certain susceptible patients.

How should CoAprovel be stored and disposed of?

How to Store and Dispose of CoAprovel?

CoAprovel (irbesartan/hydrochlorothiazide) tablets must be stored according to specific regulatory guidelines to maintain their stability and effectiveness.

Storage Conditions

Requirement Specific Instruction
Temperature Do not store above 30°C (86°F).
Protection Keep the tablets in the original package (blister/carton) to protect them from light and moisture.
Shelf Life The labeled shelf life for the unopened product is 2 years.

Handling and Disposal

No special requirements are documented regarding the handling or disposal of this finished product. If you have unused medicine, dispose of it according to the instructions provided by your pharmacist or local waste disposal authority. Do not dispose of medicines via wastewater or household garbage.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of CoAprovel  found in:

A-Z Index: